Since the concomitant administration of a gonadotrophin-releasing hormone (GnRH) 
. Similar observations have been made using GnRH agonists both in the non-human primate Mann, Gould, Smith et al. 1987) and in man (Linde, Doelle, Alexander et al. 1981; Doelle, Alexander, Evans et al. 1983 ). When, however, testosterone substitution was provided to non-human primates treated with a GnRH agonist at a time when testicular regression had occurred, no stimulation of sperm production was seen (Akhtar, Marshall, Wickings & Nieschlag, 1983; Respondek, Themann & Nieschlag, 1987 ) . This observation suggests that the stimulatory action of testosterone on spermatogenesis might be less pro¬ nounced on the regressed testis. That more testoster¬ one is needed for restoration than for maintenance of spermatogenesis has already been well established for the rat (Harris, Bartke, Weisz & Watson, 1977) .
Since GnRH antagonists appear more effective than agonists in suppressing testicular function and may have a greater potential for regulation of male fertility (Vickery, 1985) , the present study investigated whether treatment with a GnRH antagonist and delayed testosterone substitution provides a regimen for sustained induction of azoospermia in a non-human primate model. In addition, serum levels ofinhibin were evaluated as a potential marker of Sertoli cell function.
MATERIALS AND METHODS

Animals
Ten adult male cynomolgus monkeys (Macaca fascicularis), weighing 5-0-8-2 kg were used. They were maintained under controlled environmental conditions as described previously (Weinbauer et al. 1984) . Study protocol The monkeys were divided into two groups of five animals. Daily s.c. injections of the GnRH antagonist at a dose of 450 pg/kg (group 1) and 900 pg/kg (group 2) were given over a period of 18 weeks. (Schürmeyer, Wickings, Freischem & Nieschlag, 1983) . The lower limit of detection was 7-2 pmol/tube. The intra-and interassay coefficients of variation were 3-8 and 5-8% respectively. Serum LH bioactivity was measured in triplicate by in-vitro bioassay using mouse Leydig cells as described previously (Wickings, Qazi & Nieschlag, 1979) . The lowest detectable activity was 2-68 IU LER 907/1. The intra-and interassay vari¬ ations were 13-3 and 22-0%. Serum levels of inhibin were determined by a radioimmunoassay validated recently for monkey serum (Fingscheidt, Weinbauer, Robertson et al. 1989 ). The assay sensitivity was 0-27 U/ml and the intra-assay variation was 5%.
Semen analysis Ejaculates were collected by rectal probe ejaculation (Wickings & Nieschlag, 1980 Pretreatment serum concentrations of inhibin were 3-95+ 0-4 U/ml in group 1 and 4-25+ 0-9 U/ml in group 2 (Fig. 1) Sperm counts in both groups started to decline dur¬ ing weeks 4-6 of GnRH antagonist treatment (Fig. 3) . (Weinbauer et al. 1987 (Weinbauer et al. /3, 1988 . The present study, however, demonstrates that a 6-week delay of the tes¬ tosterone substitution leads to complete azoospermia. No stimulation of sperm production occurred over a period of 12 weeks, which represents approximately twice the time-interval required for the development of spermatogonia into elongated spermatids in the macaque (Clermont, 1972) .
In a previous investigation, concomitant adminis¬ tration of a GnRH antagonist and the same mode and dose of testosterone administration prevented the induction of sustained azoospermia (Weinbauer et al. 1988 ). Serum levels of testosterone achieved by the testosterone ester in the previous study were similar to those in the present investigation (28-7+1-2 compared with 24-3+ 1-3 nmol/1). It thus appears that more testosterone is required to restimulate spermato¬ genesis than to maintain the spermatogenic process. Accordingly, supraphysiological levels of testosterone given to rhesus monkeys 10 weeks after transection of the pituitary stalk restimulated sperm production (Marshall, Wickings, Lüdecke & Nieschlag, 1983) . Similarly, in hypophysectomized rats, supra-normal serum levels of testosterone were required to restimulate spermatogenesis (Boccabella, 1963; Huang, Marshall, Rosenberg & Nieschlag, 1987) (Au, Robertson & de Kretser, 1985; Morris, Vale, Cappel & Bardin, 1988) .
In agreement with the observation in rats, levels of inhibin were not stimulated by testosterone in the present study.
As in the rat (Steinberger & Steinberger, 1976; LeGac & de Kretser, 1982) , in the non-human primate Sertoli cells also produce inhibin (Noguchi, Keeping, Winters et al. 1987) . Following termination of GnRH antagonist treatment, serum levels of inhibin started to rise after about 7 weeks. One week later, testicular volumes started to recover, and 6-8 weeks later sperm appeared in the ejaculates. The duration of spermato¬ genesis in the cynomolgus monkeys is assumed to be 6 weeks (van Alphen, van de Kant & de Rooij, 1988) . Thus the increase of inhibin apparently coincided with the resumption of Sertoli cell activity and spermatogenesis. Sertoli cells are involved both in the restoration of testicular size, for example by secreting fluid and building up the seminiferous tubule lumen (Waites & Gladwell, 1982) , and in the restimulation of spermatogenesis. Therefore, the measurement ofserum levels of inhibin, at least under these experimental conditions, might be useful for assessing Sertoli cell activity.
In the present study, all monkeys lost body weight (range 4-21%). A similar reduction of body weight was observed in previous studies with different GnRH antagonists (Weinbauer et al. 1984 (Weinbauer et al. , 1987o, 1988 , while daily injection of the GnRH antagonist vehicle did not affect body weight (Weinbauer et al. 1987/3) .
Treatment with the GnRH antagonist did not reduce food or water intake (Weinbauer et al. 1987/3) . The loss of body weight during treatment with GnRH antagonists could be related to the suppression of androgen production. During concomitant treatment with the GnRH antagonist and testosterone, the body weight decrease was less pronounced (Weinbauer et al. 1987 ) when compared with the administration of GnRH antagonist alone (Weinbauer et al. 1984) .
In summary, treatment with GnRH antagonist and delayed supplementation with testosterone proved successful for sustained and reversible inhibition of sperm production in a non-human primate model. This treatment regimen might be useful for further investigations during development of an endocrine male contraceptive. The observations also suggest that inhibin secretion is under pituitary control and that during restoration of testicular size, serum levels of inhibin seem to indicate Sertoli cell activity.
